Profil
Pieter Spee is currently the Chief Scientific Officer at Pure Biologics SA since 2023.
Prior to this, he worked as the Scientific Director-Translational Immunology at Novo Nordisk A, Chief Scientific Officer at TikoMed AB, and Chief Technology Officer at FibroTx OÜ.
He obtained his doctorate degree from the University of Leiden in 1996.
Postes actifs de Pieter Spee
| Sociétés | Poste | Début |
|---|---|---|
| PURE BIOLOGICS S.A. | Directeur Technique/Scientifique/R&D | 26/05/2023 |
Anciens postes connus de Pieter Spee
| Sociétés | Poste | Fin |
|---|---|---|
FibroTx OÜ | Directeur Technique/Scientifique/R&D | - |
TikoMed AB
TikoMed AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Directeur Technique/Scientifique/R&D | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Formation de Pieter Spee
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
University of Leiden
University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TikoMed AB
TikoMed AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Pure Biologics SA
Pure Biologics SA BiotechnologyHealth Technology Operates as a a biopharmaceutical company which develops biological medicines, diagnostic tests and medical devices with therapeutic use | Health Technology |
FibroTx OÜ |
















